Common Stock and Warrant Purchase Agreement



 Exhibit 10.3 
  
 COMMON STOCK AND WARRANT PURCHASE AGREEMENT 
  
 CORAUTUS GENETICS INC. 
  
 AND 
  
 PURCHASERS 
  
 JULY 7, 2004 
  









 COMMON STOCK AND WARRANT PURCHASE AGREEMENT 
  
 THIS COMMON STOCK AND WARRANT PURCHASE AGREEMENT (this
“Agreement”) is made and entered into as of the 7th day of July, 2004 by and among Corautus
Genetics Inc., a Delaware corporation (the “Company”), and the persons or entities listed on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”). 
  
 IN CONSIDERATION OF the premises and the mutual representations and
warranties, agreements and covenants hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchasers agree as follows: 
  
 ARTICLE 1 
  
 Definitions 
  
 1.1 Certain Defined Terms. For purposes of this Agreement, the following capitalized terms shall have the following respective meanings:

  
 (a) “Claims and Losses”
means, with respect to any Person, any and all claims, actions, suits, judgments, settlements, liabilities, losses, damages, awards, interest, penalties, costs and expenses (including, without limitation, reasonable attorneys’ fees) actually
suffered or incurred by such Person. 
  
 (b)
“Common Stock” means the common stock, par value $0.001 per share, of the Company. 
  
 (c) “Company Disclosure Schedule” means the disclosure schedule of the Company attached hereto as Exhibit D.

  
 (d) “Clinical Event” means
the occurrence of at least one patient being treated under the Phase II b clinical trial sponsored by the Company pursuant to Protocol VEGF2-CAD-CL-007, entitled “A Multicenter, Randomized, Double-Blind, Dose Ranging Placebo-Controlled Study
Evaluating Defined Doses Of Percutaneously Delivered Via Boston Scientific Corporation Stiletto(tm) Endocardial Injection Catheter pVGI.1 (VEGF2) (Placebo, 20, 200, Or 800μG) In Patients With Class III Or IV Angina. 
  
 (e) “Exchange Act” means the Securities
Exchange Act of 1934, as amended. 
  
 (f)
“Material Adverse Effect” means, with respect to any Person, any circumstance, change or effect that: (i) is or is reasonably likely to be materially adverse to the business, assets, operations, results of operations, prospects,
liabilities (including, without limitation, contingent liabilities) or the financial condition of such Person and its Subsidiaries, taken as a whole, or (ii) is reasonably likely to materially adversely effect the ability of such Person to
consummate the transactions contemplated by this Agreement. 
  

 1 








 (g) “Person” means any individual, partnership, firm, corporation,
limited liability company, association, trust, unincorporated organization or other entity, as well as any syndicate or group that would be deemed a person under Section 13(d)(3) of the Exchange Act. 
  
 (h) “Preferred Stock” means the preferred
stock, par value $0.001 per share, of the Company. 
  
 (i) “Prospectus” means a prospectus, including any amendment or supplement thereto, included in the Registration Statement at the time of its effectiveness. 
  
 (j) “Registration Statement” means a registration statement on Form S-3 or another
appropriate form filed by the Company with the SEC covering the resale, from time to time, of the Shares and Warrant Shares by the Purchasers. 
  
 (k) “SEC” means the Securities and Exchange Commission. 
  
 (l) “SEC Reports” means (i) the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2003, (ii) the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2004, (iii) all proxy statements relating to the Company’s meetings of stockholders (whether annual or special) held
since January 1, 2004, and (iv) all other forms, reports and other registration statements (other than the Quarterly Report on Form 10-Q not referred to in clause (ii) above) filed by the Company with the SEC since January 1, 2004. 
  
 (m) “Securities Act” means the Securities
Act of 1933, as amended. 
  
 (n)
“Strategic Event” means any merger, consolidation or other business combination, sale of shares of capital stock, sale of assets, tender offer, exchange offer or similar transactions or series of transactions involving the Company
or material development in the Company’s product approval that has not been publicly announced. 
  
 (o) “Subsidiary” means, with respect to any Person, any corporation, partnership, joint venture, limited liability
company or other entity, whether incorporated or unincorporated, of which such Person or any other Subsidiary of such Person (i) owns, directly or indirectly, fifty percent (50%) or more of the outstanding voting securities or equity interests, (ii)
is entitled to elect at least a majority of the board of directors or similar governing body, or (iii) is a general partner, excluding such partnerships where such Person or any Subsidiary of such Person do not have a majority of the voting
interests in such partnership. 
  
 (p)
“Trading Day” means (a) any day on which the Common Stock is listed or quoted and traded on its primary Trading Market, (b) if the Common Stock is not then listed or quoted and traded on its Trading Market, then a day on which
trading occurs on the American Stock Exchange (or any successor thereto), or (c) if trading ceases to occur on the American Stock Exchange (or any successor thereto), any business day. 
  
 (q) “Trading Market” means the American Stock Exchange. 
  

 2 








 1.2 Additional Definitions. The following capitalized terms have the meanings set forth in the
Sections of this Agreement set forth below: 
  

			
	 Definition

	  	Location


	 “Agreement”
	  	Preamble
	 “Closing”
	  	3.1
	 “Closing Date”
	  	3.1
	 “Company”
	  	Preamble
	 “Company Indemnified Party”
	  	7.3
	 “First Closing”
	  	3.1
	 “Notice”
	  	8.1
	 “Option Period”
	  	2.4
	 “Purchase Price”
	  	2.3
	 “Purchaser” or “Purchasers”
	  	Preamble
	 “Purchaser Indemnified Party”
	  	7.2
	 “Second Closing”
	  	2.4
	 “Shares”
	  	2.1
	 “Unit”
	  	2.1
	 “VGI”
	  	4.1
	 “Warrant” or “Warrants”
	  	2.1
	 “Warrant Shares”
	  	2.1

  
 ARTICLE 2

  
 Purchase and Sale of Common Stock and Warrants

  
 2.1 Units. For purposes of this Agreement, each
“Unit” means and shall be comprised of four (4) shares (the “Shares”) of the Company’s Common Stock and the right to purchase one (1) share of the Company’s Common Stock at an exercise price per share
equal to one hundred twenty percent (120%) of the closing price of one share of the Company’s Common Stock on the Trading Market on the Trading Day immediately preceding the Closing Date therefor. The foregoing right shall be aggregated for
each Purchaser and represented by a warrant (each a “Warrant” and collectively the “Warrants”) to purchase such shares of the Company’s Common Stock (the “Warrant Shares”) in substantially the
form set forth in Exhibit B attached hereto. For clarification, the exercise price per share for each Warrant to be issued in connection with the First Closing shall be equal to one hundred twenty percent (120%) of the closing price of one
share of the Company’s Common Stock on the Trading Market on the Trading Day immediately preceding the First Closing and the exercise price per share for each Warrant to be issued in connection with the Second Closing shall be equal to one
hundred twenty percent (120%) of the closing price of one share of the Company’s Common Stock on the Trading Market on the Trading Day immediately preceding the Second Closing. 
  
 2.2 Purchase and Sale of Units. Subject to the terms and conditions of this Agreement, the Company will issue and
sell to each Purchaser, and each Purchaser will purchase from the Company, one-half of the number of Units set forth opposite such Purchaser’s name on 

  

 3 








 
the schedule of Purchasers set forth in Exhibit A attached hereto. The maximum number of Units issuable hereunder is 471,738 (comprising 1,886,952
Shares and Warrants for 471,738 Warrant Shares). The obligations of the Purchasers hereunder are several and not joint. 
  
 2.3 Allocation of Purchase Price. The purchase price payable by each Purchaser for the Units to be purchased hereunder (the “Purchase
Price”) shall be equal to the number of Units to be purchased by such Purchaser multiplied by $20.88 (the “Per Unit Purchase Price”), as set forth opposite such Purchaser’s Name on the schedule of Purchasers set forth in
Exhibit A attached hereto. The Purchase Price for each Unit shall be allocated as follows: (a) $5.2175 of each Unit shall be allocated to each Share contained in such Unit; and (b) $0.01 of each Unit shall be allocated to the right to
purchase one share of Common Stock represented by the Warrant. 
  
 2.4 Second Closing. 
  
 (a) In
the event that prior to April 7, 2005 (the “Option Period”), a public announcement of the Clinical Event has occurred, the Company shall have the right to require a second closing (the “Second Closing”) pursuant to which the
Company shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, one-half of such number of Units as set forth opposite such Purchaser’s name in Exhibit A attached hereto at
the Per Unit Purchase Price, which shall be in addition to the Units purchased under Section 2.2. The Second Closing shall occur within two (2) business days after the public announcement of the Clinical Event. At the Second Closing, the Company
shall deliver or cause to be delivered to each Purchaser the following: (i) a Warrant, registered in the name of such Purchaser, pursuant to which such Purchaser shall have the right to acquire such number of Warrant Shares as set forth opposite
such Purchaser’s name on Exhibit A under the heading “Second Closing Warrant Shares,” on the terms set forth therein; (ii) an instruction letter to the Transfer Agent in the form set forth on Exhibit C hereto; and (iii)
a certificate from a duly authorized officer certifying on behalf of the Company that a public announcement of the Clinical Event has occurred. At the Second Closing, each Purchaser shall instruct the Escrow Agent to deliver an amount equal to the
Per Unit Purchase Price multiplied by one-half of the number of Units as set forth opposite such Purchaser’s name on Exhibit A, in United States dollars and in immediately available funds, by wire transfer to an account designated in
writing to such Purchaser by the Company for such purpose, and the Company shall consent to such instruction. Each Purchaser shall have the right, at any time during the Option Period, to request a Second Closing and to purchase on the terms
provided herein up to the total amount of the Units that could be purchased by such Purchaser at the Second Closing. 
  
 (b) At the time of the First Closing, each Purchaser shall deliver the Purchase Price for the Second Closing set forth in Section 2.4(a)
(the “Escrow Funds”) to Proskauer Rose LLP (the “Escrow Agent”), to be held by the Escrow Agent in escrow on behalf of such Purchaser. Upon the occurrence of the public announcement of the Clinical Event during the Option Period,
the Escrow Agent shall release the Escrow Funds to the Company as provided in the Escrow Agreement. In the event that the public announcement of the Clinical Event does not occur prior to the termination of the Option Period, the Escrow Agent shall
return the Escrow Funds to the Purchasers as provided in the Escrow Agreement. 
  

 4 








 ARTICLE 3 
  

Closing and Deliverables 
  
 3.1 The Closing. Subject to the terms and conditions of this Agreement, the closing of the purchase and sale of the Units pursuant to Section 2.2
hereof (the “First Closing”) will take place at a closing to be held at the offices of McKenna Long & Aldridge LLP, 303 Peachtree Street, Suite 5300, Atlanta, Georgia 30308, on July 7, 2004 at 2:00 p.m. local time or such other time as
may be agreed upon by the Company and the Purchasers; provided, however, the Company shall schedule an alternative closing with respect to a particular Purchaser on such other date as the Company and such Purchaser may mutually agree
but in any event not later than July 14, 2004. The First Closing and each additional closing are referred to herein individually as a “Closing,” and the date of the First Closing and the date of each additional closing are referred
to herein individually as a “Closing Date.” 
  
 3.2 Deliverables and Conditions to Closing. 
  
 (a) Conditions to the Company’s Obligations. The Company’s obligations to complete the purchase and sale of the Units and to deliver the stock certificate(s) and Warrant(s) therefor to each Purchaser
is subject to (i) receipt by the Company of immediately available funds in the full amount of the Purchase Price for the Units being purchased hereunder as set forth opposite such Purchaser’s name on Exhibit A attached hereto, and (ii)
approval from the Trading Market to list the Shares and Warrant Shares on the Trading Market. 
  
 (b) Conditions to the Purchaser’s Obligations. Each Purchaser’s obligation to complete the purchase and sale of the Units
is subject to delivery by the Company to such Purchaser of (i) a certificate, dated as of the Closing Date, executed by a duly authorized officer of the Company, to the effect that the representations and warranties of the Company set forth in
Article 4 below are accurate in all material respects as of the Closing Date and to the effect that the Company has fulfilled in all material respects those undertakings of the Company to be fulfilled on or prior to the Closing, (ii) instructions in
the form of Exhibit C attached hereto to the Company’s transfer agent to deliver to such Purchaser one or more stock certificates issued in the name of such Purchaser, or in such nominee name(s) as designated by such Purchaser in
writing, representing the number of Shares set forth opposite such Purchaser’s name on the schedule of Purchasers set forth in Exhibit A attached hereto under the heading “First Closing Shares,” (iii) a Warrant to purchase the
number of Warrant Shares set forth opposite such Purchaser’s name on the schedule of Purchasers set forth in Exhibit A attached hereto under the heading “First Closing Warrant Shares,” (iv) a legal opinion of Company counsel,
substantially in the form of Exhibit B, executed by such counsel and delivered to the Purchasers, and (v) approval from the Trading Market to list the Shares and Warrant Shares on the Trading Market. 
  
 ARTICLE 4 
  
 Representations, Warranties and Covenants of the Company 
  
 Except as set forth in the Company’s SEC Reports or on the corresponding sections of the Company Disclosure Schedule,
or as specifically contemplated by this Agreement, the 

  

 5 








 
Company hereby represents and warrants to, and covenants with, each Purchaser as of the Closing Date as follows: 
  
 4.1 Organization and Qualification; Subsidiaries. The Company is a
corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all necessary corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and
to carry on its business as it is currently conducted. The Company is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the properties owned or leased by it or the operation of its business makes such
licensing or qualification necessary, except where the failure to be so licensed or qualified would not have a Material Adverse Effect. Other than Urogen Acquisition Corporation and Vascular Genetics Inc. (“VGI”), the Company does
not own, of record or beneficially, any direct or indirect equity or other interest in any Subsidiary. 
  
 4.2 Authority, Enforcement and Validity. The Company has all necessary corporate power and authority to enter into this Agreement, to carry out its
obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by the Company of this Agreement, the performance by the Company of its obligations hereunder and the consummation by the Company of the
transactions contemplated hereby have been duly authorized by all requisite action on the part of the Company. This Agreement has been duly executed and delivered by the Company, and (assuming due execution and delivery hereof by each other party
hereto) this Agreement constitutes, or upon its execution shall constitute, the legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject to (i) the effect of any applicable bankruptcy,
insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights and remedies generally, and (ii) the effect of general equitable principles, regardless of whether asserted in a proceeding in equity
or at law. 
  
 4.3 Capitalization. The authorized
capital stock of the Company consists of 100,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock (of which Preferred Stock there are designated 40,000 shares of Series A Preferred Stock, 13,000 shares of Series B Preferred Stock,
17,000 shares of Series C Preferred Stock and 1,400,000 shares of Series D Preferred Stock). As of June 30, 2004, (a) 12,572,491 shares of Common Stock are issued and outstanding, (b) 2,829,170 shares of Common Stock are reserved for issuance
pursuant to options granted pursuant to the Company’s 1995 Stock Plan, 1995 Directors Option Plan, 1999 Stock Plan, and 2002 Stock Plan, (c) 1,005,127 shares of Common Stock are reserved for issuance upon the exercise of outstanding warrants,
(d) 2,000 shares of Series C Preferred Stock are issued and outstanding, (e) 1,385,377 shares of Series D Preferred Stock are issued and outstanding, (f) 556,904 shares of Common Stock are reserved for issuance to the former stockholders of VGI to
indemnify such stockholders against certain losses as set forth in an Agreement and Plan of Reorganization dated September 12, 2002, as amended, between the Company and VGI, (g) 250,012 shares of Common Stock are reserved for the Convertible Notes
Payable from Boston Scientific Corporation, (h) 142,857 shares of Common Stock are reserved for issuance under the Company’s Employee Stock Purchase Plan, and (i) 18,178 shares of Common Stock are reserved for issuance to Pacific Management
Services, Inc. pursuant to a settlement agreement relating to a facility formerly leased by the Company. Except as set forth in this Section 4.3, in the Company’s SEC Reports or in the Company Disclosure Schedule, there 

  

 6 








 
are no outstanding options, warrants, subscriptions, calls, convertible securities or other rights, agreements, arrangements or commitments relating to the
capital stock of the Company or obligating the Company to issue or sell any shares of capital stock of, or any other equity interest in, the Company, excluding occasional grants of options to members of the Company’s Board of Directors for
attendance at meetings pursuant to established policies. 
  
 4.4
Issuance of Shares. The Shares and Warrants to be issued and sold pursuant to this Agreement have been duly and validly authorized by the Company, and, at the Closing, the Shares and Warrants will have been duly and validly issued, fully paid
and non-assessable, and the issuance of the Shares and Warrants shall not be subject to preemptive or other similar rights, except for such rights that have been waived. The Warrant Shares, if and when issued, sold and delivered in accordance with
the terms of the Warrants, will be duly and validly issued, fully paid and non-assessable, and the issuance of such Warrant Shares shall not subject to any preemptive or similar rights, except for such rights that have been waived. 
  
 4.5 No Conflict. The execution, delivery and performance by the
Company of this Agreement and the consummation by the Company of the transactions contemplated hereby does not (a) violate, conflict with or result in the breach of any provision of its certificate of incorporation or by-laws, (b) conflict with or
violate any law, rule, regulation, order, judgment or decree applicable to the Company or any of its Subsidiaries, or (c) conflict with, result in any breach of, constitute a default under, require any consent under, or give to others any rights of
termination, amendment, acceleration, suspension, revocation or cancellation of any material agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, except for any such conflicts, violations, breaches, defaults
or other occurrences that have not had, and would not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. 
  
 4.6 Governmental Consents and Approvals. The execution, delivery and performance of this Agreement by the Company does not require any consent,
approval, authorization or other order of, action by, filing with or notification to, any governmental authority other than (a) any approval of, filing with or notification to the American Stock Exchange, including the approval of the listing of the
Shares and Warrant Shares on such exchange, and (b) such registrations, filings and authorizations as may be required under applicable federal and state securities laws, including, without limitation, the Registration Statement and a declaration as
to the effectiveness of such Registration Statement. 
  
 4.7
SEC Reports. The Company has filed all forms, reports and documents required to be filed by it with the SEC pursuant to the reporting requirements of the Exchange Act during the twelve (12) months preceding the date of this Agreement. As of
their respective filings dates, the Company’s SEC Reports (a) were prepared in accordance with either the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC promulgated
thereunder, and (b) did not, at the time they were filed, or, if amended, as of the date of such amendment, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make
the statements made therein, in the light of the circumstances under which they were made, not misleading. 
  

 7 








 4.8 Financial Statements. Each of the consolidated financial statements (including, in each case,
any notes thereto) contained in the Company’s SEC Reports was prepared in accordance with United States generally accepted accounting principles applied on a consistent basis throughout the periods indicated (except as may be indicated in the
notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q of the SEC), and each fairly presents, in all material respects, the consolidated financial position, results of operations and cash flows of the Company and its
consolidated Subsidiaries as at the respective dates thereof and for the respective periods indicated therein (subject, in the case of unaudited statements, to normal and recurring year-end adjustments which would not have had, and would not have, a
Material Adverse Effect). 
  
 4.9 Absence of Certain
Changes. Except as set forth in the Company’s SEC Reports or in Section 4.9 of the Company Disclosure Schedule, since the date of the balance sheet in the Company’s most recently filed SEC Report, the business of the Company has been
conducted in the ordinary course, in a manner consistent with past practices and there has been no Material Adverse Effect. 
  
 4.10 Litigation. Except as set forth in the Company’s SEC Reports or in Section 4.10 of the Company Disclosure Schedule, there is no action,
suit, proceeding, inquiry or investigation before any court, public board, government agency, self-regulatory agency or other body pending or, to the knowledge of the Company, threatened by or against the Company or either of its two Subsidiaries
which has resulted or would reasonably be expected to have a Material Adverse Effect. 
  
 4.11 Disclosure. Except as set forth on Section 4.11 of the Company Disclosure Schedule, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or
their agents or counsel with any information that constitutes or might constitute material, non-public information. 
  
 4.12 Use of Proceeds. The Company intends to use the net proceeds from the sale of the Units hereunder for general corporate and working capital
purposes. 
  
 4.13 Certain Fees. Except for the fees to
Ashenden Finance & Cie SA as to Purchasers other than the Walters Group and for agreements the Company may make in connection with the Walters Group, no brokerage or finder’s fees or commissions are or will be payable by the Company to any
broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement, and the Company has not taken any action that would cause any Purchaser to be
liable for any such fees or commissions. 
  
 4.14 Internal
Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and 

  

 8 








 
appropriate action is taken with respect to any differences, except where such noncompliance could not be reasonably expected to have, individually or in the
aggregate, a Material Adverse Effect. 
  
 4.15 Sarbanes-Oxley
Act. The Company is in compliance with applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the Commission thereunder in effect as of the date of this Agreement, except where such
noncompliance could not be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. 
  
 4.16 Reservation of Securities. The Company shall maintain a reserve from its duly authorized shares of Common Stock for issuance pursuant to this
Agreement and the Warrants in such amount as may be required to fulfill its obligations in full under this Agreement and the Warrants. In the event that at any time the then authorized shares of Common Stock are insufficient for the Company to
satisfy its obligations in full under this Agreement and the Warrants, the Company shall promptly take such actions as may be required to increase the number of authorized shares. 
  
 4.17 Subsequent Placements. From the date hereof until the effective date of the Registration Statement, the Company
will not, directly or indirectly, offer, sell, grant any option to purchase (other than to Boston Scientific Corporation and the Company’s officers, directors, and employees), or otherwise dispose of (or announce any offer, sale, grant or any
option to purchase, or otherwise dispose of) any of its equity or equity equivalent securities, including without limitation any debt, preferred stock or other instrument or security that is, at any time during its life and under any circumstances,
convertible into or exchangeable or exercisable for Common Stock. 
  
 4.18 Private Placement. Neither the Company nor any Person acting on the Company’s behalf has sold or offered to sell or solicited any offer to buy the Units by means of any form of general solicitation or advertising. Neither
the Company nor any of its affiliates nor any Person acting on the Company’s behalf has, directly or indirectly, at any time within the past six months, made any offer or sale of any security or solicitation of any offer to buy any security
under circumstances that would eliminate the availability of the exemption from registration under Regulation D under the Securities Act in connection with the offer and sale of the Units as contemplated hereby. The Company is not, and is not an
Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. The Company is not a United States real property holding corporation within the meaning of the Foreign Investment in Real Property
Tax Act of 1980. 
  
 ARTICLE 5 
  
 Representations, Warranties and Covenants of Each Purchaser 

 
 Except as specifically contemplated by this Agreement, each Purchaser,
severally and not jointly, hereby represents and warrants to, and covenants with, the Company as of the Closing Date as follows: 
  
 5.1 Organization. Such Purchaser is an entity duly organized, validly existing and in good standing under the laws of its state of organization and
has all necessary power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on its business as it is currently conducted. 
  

 9 








 5.2 Authority, Enforcement and Validity. Such Purchaser has all necessary power and authority to
enter into this Agreement, to carry out its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by such Purchaser of this Agreement, the performance by such Purchaser of its obligations hereunder
and the consummation by such Purchaser of the transactions contemplated hereby have been duly authorized by all requisite action on the part of such Purchaser. This Agreement has been duly executed and delivered by such Purchaser, and (assuming due
execution and delivery hereof by the Company) this Agreement constitutes, or upon its execution shall constitute, the legal, valid and binding obligation of such Purchaser enforceable against such Purchaser in accordance with its terms, subject to
(i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights and remedies generally, and (ii) the effect of general equitable principles, regardless of
whether asserted in a proceeding in equity or at law. 
  
 5.3
Accredited Investor and Investment Experience. Such Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation D promulgated under the Securities Act. In addition, such Purchaser is knowledgeable,
sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities representing an investment decision like that involved in the purchase of the Shares and Warrants. 
  
 5.4 Investment Intent. Such Purchaser is acquiring the Units for its
own account solely for the purpose of investment and not as a nominee or agent and not with a view to, or for offer or sale in connection with, any distribution thereof. Such Purchaser shall not, directly or indirectly, offer, sell, pledge, transfer
or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares, Warrants or Warrant Shares except in accordance with the provisions of Article 6 of this Agreement. 
  
 5.5 Information and Risk. 
  
 (a) Such Purchaser has requested, received, reviewed and
considered all information such Purchaser deems relevant in making an informed decision to purchase the Shares and Warrants. Such Purchaser has had an opportunity to discuss the Company’s business, management and financial affairs with its
management and also had an opportunity to ask questions of officers of the Company that were answered to such Purchaser’s satisfaction, provided that such inquiries do not impair the rights of such Purchaser to rely on the representations and
warranties of the Company as set forth in Article 4. 
  
 (b) Such Purchaser recognizes that an investment in the Shares and Warrants involves a high degree of risk, including a risk of total loss of such Purchaser’s investment. Such Purchaser is able to bear the economic risk of holding the
Shares and Warrants for an indefinite period or complete loss of the investment, and has knowledge and experience in the financial and 

  

 10 








 
business matters such that it is capable of evaluating the risks of the investment in the Shares and Warrants. 
  
 (c) Such Purchaser has, in connection with such
Purchaser’s decision to purchase the Shares and Warrants, not relied upon any representations or other information (whether oral or written) other than as set forth in the representations and warranties of the Company contained herein and the
SEC Reports, and such Purchaser has, with respect to all matters relating to this Agreement and the offer and sale of the Shares and Warrants, relied solely upon the advice of such Purchaser’s own counsel and has not relied upon or consulted
any counsel to the Company. 
  
 5.6 Disclosures to the
Company. Such Purchaser understands that the Company is relying on the statements contained herein to establish an exemption from registration under applicable federal and state securities laws. Such Purchaser will promptly notify the Company of
any changes in the information set forth in the Registration Statement or Prospectus regarding such Purchaser. For purposes of the requirements of state securities laws, such Purchaser represents that it is solely a resident of the state set forth
opposite such Purchaser’s name on Exhibit A attached hereto and that the offer and purchase of the Shares and the Warrants pursuant hereto has and will occur solely in such state. 
  
 5.7 Legends. 
  
 (a) Such Purchaser understands that, until such time as the
Shares and the Warrant Shares into which the Warrant is convertible may be sold under an effective registration statement under the Securities Act, or an exemption under the Securities Act and applicable state securities laws, the Shares and the
Warrant Shares into which the Warrant is convertible will bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such securities): 
  
 “The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any other jurisdiction. These securities have been acquired for investment and not with a view to, or in connection with, the
distribution thereof. The securities may not be offered, sold, pledged, transferred or assigned in the absence of an effective registration statement for the securities under the Securities Act and applicable state securities laws, unless sold
pursuant to an exemption under the Securities Act and applicable state securities laws.” 
  
 (b) Such certificates shall not be required to contain such legend (i) following any sale of such Shares and Warrant Shares pursuant to
Rule 144, or (ii) if such Shares and Warrant Shares are eligible for sale under Rule 144(k). Following the effective date of the Registration Statement or at such earlier time as a legend is no longer required for certain Shares or Warrant Shares,
the Company will use commercially reasonable efforts to, no later than three (3) Trading Days following the delivery by a Purchaser to the Company or its transfer agent of a legended certificate representing such securities, deliver or cause to be
delivered to such 

  

 11 








 
Purchaser a certificate representing such securities that is free from all restrictive and other legends. 
  
 5.8 Nature of Purchaser. Except as set forth in Exhibit A
attached hereto, such Purchaser: (a) is not an affiliate (as such term is defined pursuant to Rule 12b-2 promulgated under the Exchange Act) of any other Purchaser; (b) is not constituted as a partnership, association, joint venture or any other
type of joint entity with any other Purchaser; and (c) is in no way acting as a group (as such term is defined under Section 13(d) of the Exchange Act) with any other Purchaser. If at any time after the Closing Date such Purchaser becomes an
affiliate (as defined herein) of any other Purchaser, such Purchaser will provide prompt written notice to the Company. 
  
 5.9 Disclosure. Except for Iroquois Capital, L.P., each Purchaser confirms that neither it nor any other Person acting on its behalf has
received any information that constitutes or might constitute material, non-public information. 
  
 5.10 Brokers and Finders. No broker, investment banker, financial advisor or other Person is entitled to any broker’s, finder’s,
financial advisor’s or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of any Purchaser, except as may be paid to Ashenden Financie & Cie SA and
The Walters Group. 
  
 ARTICLE 6 
  
 Registration of the Shares; Compliance with the Securities Act

  
 6.1 Registration Procedures and Expenses.

  
 (a) Except for such times as the Company may
be required to suspend the use of a prospectus forming a part of the Registration Statement, the Company will: 
  
 (1) as soon as practicable, but in no event later than thirty (30) days following the Closing Date, use commercially reasonable efforts to
prepare and file with the SEC a Registration Statement; 
  
 (2) use commercially reasonable efforts to cause the Registration Statement to become effective under the Securities Act as soon as practicable, but in no event later than one hundred twenty (120) days after the
Closing Date, and to cause the Shares and Warrant Shares to be listed on the Trading Market as soon as practicable; 
  
 (3) prepare and file with the SEC such amendments and supplements to the Registration Statement and the prospectus used in connection
therewith as may be necessary to keep the Registration Statement continuously effective until the earliest of (i) when all Shares and Warrant Shares can be sold pursuant to Rule 144(k) under the Securities Act, or (ii) such time as all Shares and
Warrant Shares purchased by the Purchasers have been sold; 
  
 (4) so long as the Registration Statement is effective covering the resale of Shares owned by the Purchasers, furnish to the Purchasers with respect to the Shares 

  

 12 








 
registered under the Registration Statement (and to each underwriter, if any, of such Shares) such reasonable number of copies of prospectuses and such other
documents as the Purchaser may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Shares by the Purchasers; provided, however, that the obligation of the Company to deliver copies of
prospectuses to the Purchasers shall be subject to the receipt by the Company of reasonable assurances from the Purchasers that the Purchasers will comply with the applicable provisions of the Securities Act and of such other securities laws as may
be applicable in connection with any use of such prospectuses; 
  
 (5) use commercially reasonable efforts to file documents required of the Company for normal Blue Sky clearance in states specified in writing by the Purchasers; provided, however, that the Company shall
not be required to qualify to do business or consent to service of process in any jurisdiction in which the Company is not now so qualified or has not so consented; and 
  
 (6) bear all expenses in connection with the procedures in paragraphs (a) through (c) of this Section 6.1
and the registration of the Shares pursuant to the Registration Statement, other than fees and expenses, if any, of counsel or other advisers to the Purchasers or underwriting discounts, brokerage fees and commissions incurred by the Purchasers, if
any. 
  
 (b) In the event that the Registration
Statement is not declared effective by the SEC on or before the one hundred twentieth (120th) day after the Closing
Date for a Purchaser, the Company shall pay to such Purchaser liquidated damages in a cash amount equal to one-thirtieth of one percent (1/30 of 1%) of the Purchase Price paid by such Purchaser for each day after such one hundred twentieth
(120th) day that the Registration Statement is not declared effective; provided, however, that such
fees in the aggregate shall in no event to exceed eight percent (8%) of the Purchase Price 
  
 (c) Notwithstanding any provision in this Agreement to the contrary, following the 30th Trading Day following the effective date of the
Registration Statement, the Company’s obligations hereunder to keep a registration statement continuously in effect under the Securities Act shall be suspended (a “Suspension Period”) if, in the good faith judgment of the
Company’s Board of Directors, it is advisable to suspend the use of the Prospectus included therein for a discrete period of time due to pending material corporate developments or similar material events that have not yet been publicly
disclosed and as to which the Company believes that public disclosure would be prejudicial to the Company or its stockholders; provided, that the Registration Statement shall be suspended for a total of no more than two times or for a period of more
than twenty (20) days in any twelve (12) month period. The provisions of Section 6.1(b) shall not be applicable during the Suspension Period and shall be tolled as a result of any grace period. Immediately after the end of any Suspension Period
under this Section 6.1(c), the Company shall take all actions that may be reasonably necessary (including filing any required supplemental prospectus) to restore the effectiveness of the applicable Registration Statement and the ability of the
Purchasers to publicly resell their securities pursuant to such effective Registration Statement. 
  

 13 








 (d) Each Purchaser will promptly notify the Company of any changes in the information set
forth in the Registration Statement or Prospectus regarding the Purchaser or its plan of distribution, attached hereto as Exhibit E. 
  
 6.2 Restrictions on Transferability. 
  
 (a) Each Purchaser agrees that it will not effect any disposition of the Shares that would constitute a sale within the meaning of the
Securities Act or pursuant to any applicable state securities or Blue Sky laws, except as contemplated in the Registration Statement referred to in Section 6.1, or pursuant to Rule 144 of the Securities Act or pursuant to a written opinion of legal
counsel reasonably satisfactory to the Company and addressed to the Company to the effect that registration is not required in connection with the proposed transfer; whereupon the holder of such securities shall be entitled to transfer such
securities in accordance with the terms of the notice delivered by the holder to the Company. Each certificate evidencing the securities transferred as above provided shall bear the appropriate restrictive legends set forth in Section 5.8.

  
 (b) Each Purchaser hereby covenants that such
Purchaser will not sell any Shares pursuant to said prospectus during the Suspension Period set forth under Section 6.1(c). 
  
 (c) None of the Shares shall be transferable except upon the conditions specified in this Article 6, which are intended to ensure
compliance with the provisions of the Securities Act. Each Purchaser will cause any proposed transferee of the Shares held by such Purchaser to agree to take and hold such Shares subject to the provisions and upon the conditions specified in this
Article 6 if and to the extent that such Shares continue to be restricted securities in the hands of the transferee. 
  
 6.3 Termination of Conditions and Obligations. The conditions precedent imposed by Section 6.2 above regarding the transferability of the Shares
shall cease and terminate as to any particular number of the Shares upon the date on which the Purchaser may sell without volume limitations all such Shares then held by the Purchaser without registration by reason of Rule 144 or any other rule of
similar effect. 
  
 ARTICLE 7 
  
 Indemnification 
  
 7.1 Survival of Representations and Warranties. The representations,
warranties, covenants, agreements and indemnities of the Company and each Purchaser contained in this Agreement shall survive the Closing Date and remain in full force and effect until the first anniversary of the Closing Date. 
  
 7.2 Indemnification by the Company. The Company shall indemnify,
defend and hold harmless each Purchaser, the officers, directors, partners, members and each Person, if any, who controls any Purchaser within the meaning of Section 15 of the Securities Act (each, a “Purchaser Indemnified Party”)
from and against any and all Claims and Losses actually suffered or incurred by such Purchaser Indemnified Parties arising out of or resulting from (a) any untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement 

  

 14 








 
or Prospectus, or in any amendments or supplements thereto, or any omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, or (b) the breach by the Company of any of its representations or warranties in this Agreement; provided,
however, the foregoing indemnities shall not apply to any Claims and Losses arising out of or resulting from (x) any such untrue statement or omission or alleged untrue statement or omission based upon information furnished to the Company by
any Purchaser Indemnified Party, or (y) the breach by any Purchaser of any if its representations or warranties or the failure of any Purchaser to comply with any of the covenants and agreements in this Agreement, or (z) any statement or omission in
any Prospectus that is corrected in any subsequent Prospectus that was delivered to a Purchaser prior to the pertinent sale or sales by the Purchaser. 
  
 7.3 Indemnification by each Purchaser. Each Purchaser shall severally indemnify, defend and hold harmless the Company, its directors and officers,
and each Person, if any, who controls the Company within the meaning of Section 15 of the Securities Act (each, a “Company Indemnified Party”) from and against any and all Claims and Losses actually suffered or incurred by such
Company Indemnified Parties arising out of or resulting from (a) any untrue statement of a material fact contained in the Registration Statement or Prospectus, or in any amendments or supplements thereto, or any omission to state therein a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading based upon information furnished to the Company by such Purchaser, (b) the breach by such Purchaser
of any if its representations or warranties in this Agreement, or (c) the failure of such Purchaser to comply with any of the covenants and agreements in Section 6.1(d) or 6.2 of this Agreement; provided, however, the foregoing
indemnities shall not apply to any Claims and Losses arising out of or resulting from the breach by the Company of any if its representations or warranties or the failure of the Company to comply with any of the covenants and agreements in this
Agreement. 
  
 7.4 Limitations for Indemnification. In no
event shall the Company be required to indemnify any Purchaser, and its Purchaser Indemnified Parties, hereunder in excess of an amount equal to the aggregate Purchase Price paid by such Purchaser to the Company on the Closing Date. In no event
shall any Purchaser be required to indemnify the Company, and its Company Indemnified Parties, hereunder in excess of an amount equal to the aggregate Purchase Price paid by such Purchaser to the Company on the Closing Date. 
  
 7.5 Procedures for Indemnification. An indemnified party hereunder
shall notify the indemnifying party, in writing, of any claim for indemnification, specifying in reasonable detail the nature of the Claims and Losses and, if known, the amount or an estimate of the amount of the Claims and Losses. In the event of a
claim by any third party, or if there is any claim against a third party available by virtue of the circumstances of the Claims and Losses, the indemnifying party may assume the defense or the prosecution thereof by prompt written notice to
indemnified party including the employment of counsel or accountants, at its cost and expense; provided, however, if the defendants in any such action include both the indemnifying party and the indemnified party and such parties shall have
reasonable concluded that there may be a conflict between the positions of such parties in conducting the defense of any such action, the indemnified party shall have the right to select separate legal counsel to assume such defense and otherwise
participate in such action at the indemnifying party’s expense. The indemnified party 

  

 15 








 
shall have the right to employ counsel separate from counsel employed by the indemnifying party in any such action and to participate therein, but the fees
and expenses of such counsel employed by the indemnified party shall be at its expense. The indemnifying party shall not be liable for any settlement of any such Claims and Losses effected without its prior written consent, which shall not be
unreasonably withheld; provided that if the indemnifying party does not assume the defense or prosecution of a third-party claim as provided above within thirty (30) Days after notice thereof from the indemnified party, the indemnified party may
settle such claim without the indemnifying party’s consent. The indemnifying party shall not agree to a settlement of any Claims and Losses which provides for any relief other than the payment of monetary damages or which could have a material
precedential impact or effect on the business or financial condition of the indemnified party without the indemnified party’s prior written consent. Whether or not the indemnifying party chooses to so defend or prosecute such claim, both
parties shall cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials and appeals, as may be reasonably requested in connection
therewith. 
  
 ARTICLE 8 
  
 Notices 
  
 8.1 Notices Generally. Any notice, request, demand, instruction or other document to be given hereunder (a
“Notice”) by any party hereto to another party hereto shall be in writing and sent by facsimile or delivered personally or sent by registered or certified mail (including by overnight courier or express mail service), postage or
fees prepaid, and addressed as set forth in this Article 8 below. Any Notice sent by facsimile shall be deemed to have been duly given to the party to whom it is sent upon written confirmation of receipt, provided that a copy of such fax is
delivered personally or mailed to the recipient within one business day of the date of the fax, in the manner herein provided. Any Notice which is delivered personally in the manner provided herein shall be deemed to have been duly given to the
party to whom it is directed upon actual receipt by such party or the office of such party. Any Notice which is delivered by overnight courier in the manner provided herein shall be deemed to have been duly given to the party to whom it is directed
on the second business day after deposit with such overnight courier. Any Notice which is addressed and mailed in the manner herein provided shall be conclusively presumed to have been duly given to the party to which it is addressed at the close of
business, local time of the recipient, on the fourth business day after the day it is so placed in the mail or, if earlier, the time of actual receipt. 
  
 8.2 Notices to the Company. All Notices to the Company shall be addressed to the following addresses or at such other address or addresses as may
have been previously furnished to each Purchaser by Notice in accordance with this Article 8: 
  
 Corautus Genetics Inc. 
 75 Fifth Street, NW, Suite 313 
 Atlanta, GA 30308 
 Attention: Chief Executive
Officer 
  

 16 








 With a copy to: 
 McKenna Long & Aldridge LLP 
 303 Peachtree Street, Suite 5300 
 Atlanta, GA 30308 
 Attention: Robert E.
Tritt, Esq. 
  
 8.3 Notices to each Purchaser. All Notices
to any Purchaser shall be addressed to the address for such Purchaser set forth in Exhibit A attached hereto, or at such other address or addresses as may have been previously furnished to the Company by Notice in accordance with this Article
8. 
  
 ARTICLE 9 
  
 General Provisions 
  
 9.1 Governing Law and Venue. ALL QUESTIONS CONCERNING THE
CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. THE COMPANY AND PURCHASERS HEREBY IRREVOCABLY SUBMIT TO THE EXCLUSIVE
JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN FOR THE ADJUDICATION OF ANY DISPUTE BROUGHT BY THE COMPANY OR ANY PURCHASER HEREUNDER, IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVE, AND AGREE NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING BROUGHT BY THE COMPANY OR ANY PURCHASER, ANY CLAIM
THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, OR THAT SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT,
ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL
CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. THE COMPANY AND PURCHASERS HEREBY WAIVE ALL RIGHTS TO A
TRIAL BY JURY. 
  
 9.2 Fees and Expenses. At the Closing,
the Company shall pay to Iroquois Capital, L.P. an aggregate of $15,000 for their legal fees and expenses incurred in connection with its due diligence and the preparation and negotiation of this Agreement. In lieu of the foregoing payment, Iroquois
Capital, L.P. may retain such amount at the Closing. Except as expressly set forth in this Agreement to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party 

  

 17 








 
incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all transfer agent fees, stamp taxes
and other taxes and duties levied in connection with the issuance of the Shares. 
  
 9.3 Entire Agreement. This Agreement (including the Exhibits, which are incorporated herein, and the Warrants issued hereunder) constitutes the entire agreement between the Company and the Purchasers and
supersedes any prior understanding or agreement among them respecting the subject matter hereof. Except as specifically set forth herein, neither the Company nor the Purchasers make any representation, warrant, covenant or undertaking with respect
to such matters. 
  
 9.4 Amendment. This Agreement may not
be amended or modified except by an instrument in writing signed by authorized representatives of the Company and each Purchaser. 
  
 9.5 No Waiver. No waiver of any provision hereof will be valid or binding on a party hereto unless such waiver is in writing and signed by or on
behalf such party. The delay or failure of any party to enforce at any time for any period the provisions of or any rights deriving from this Agreement shall not be construed to be a waiver of such provisions or rights or the right of such party
thereafter to enforce such provisions. 
  
 9.6
Severability. In case any one or more of the provisions contained in this Agreement should be found by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect against any party, such invalidity, illegality, or
unenforceability shall only apply to such party in the specific jurisdiction where such judgment shall be made, and the validity, legality, and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired
thereby, except that this Agreement shall not be reformed in any way that will deny to any party the essential benefits of this Agreement, unless such party waives in writing its rights to such benefits. 
  
 9.7 Successors and Assigns. The terms, conditions and obligations of
this Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns. 
  
 9.8 Headings. Article, Section and other headings contained in this Agreement are inserted for convenience only and shall not be construed to
define, interpret, describe or limit the scope, extent or intent of this Agreement or any provision hereof 
  
 9.9 Counterparts and Facsimile. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, and
by the different parties in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to
this Agreement by facsimile shall be effective as delivery of a manually executed counterpart of this Agreement. 
  
 9.10 Replacement of Securities. If any certificate or instrument evidencing any securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably 

  

 18 








 
satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or
instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement securities. 
  
 9.11 Adjustments in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof, each reference
in this Agreement or the Warrants to a number of shares or a price per share shall be amended to appropriately account for such event. 
  
 9.12 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement are several and not
joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under this Agreement. The decision of each Purchaser to purchase Shares pursuant to
this Agreement has been made by such Purchaser independently of any other Purchaser and independently of any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of
operations, condition (financial or otherwise) or prospects of the Company which may have been made or given by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser or any of its agents or employees shall have any
liability to any other Purchaser (or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained herein, and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute
the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by this Agreement. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no other Purchaser will be acting as agent of such Purchaser in
connection with monitoring its investment hereunder. Each Purchaser shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser represents that it has been represented by its own separate legal counsel in its review and negotiations of this Agreement. For reasons of
administrative convenience only, the Purchasers acknowledge and agree that they and their respective counsel have chosen to communicate with the Company through Proskauer Rose LLP, but Proskauer Rose LLP represents only Iroquois Capital, L.P.

  
 <Signatures on Following Pages> 
  

 19 








 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	COMPANY:
	
	Corautus Genetics Inc., a Delaware corporation
		
	By:	 	 /s/ Richard E. Otto

	 	 	 Richard E. Otto

	 	 	 Chief Executive Officer



  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Iroquois Capital, L.P.
		
	By:	 	 /s/ Joshua Silverman

	 Name:
	 	 Joshua Silverman

	 Title:
	 	 Partner

	 	 	 
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.:
	 	 



			
	 Telephone No.:
	 	 
	 Attention: Joshua Silverman

	
	 With a copy to:

	
	 Proskauer Rose, LLP

	 1585 Broadway

	 New York, NY 10036

	 Facsimile No.: 212-969-2900

	 Telephone No.: 212-969-3689

	 Attention: Adam J. Kansler, Esq.



  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Highline Capital Partners, LP
		
	By:	 	 /s/ Jacob Doft

	 Name:
	 	 Jacob Doft

	 Title:
	 	 Managing Member

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 



			
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Highline Capital Partners, QP LP
		
	By:	 	 /s/ Jacob Doft

	 Name:
	 	 Jacob Doft

	 Title:
	 	 Managing Member

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 



			
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Highline Capital International, Ltd.
		
	By:	 	 /s/ Jacob Doft

	 Name:
	 	 Jacob Doft

	 Title:
	 	 Director

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 



			
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Bonanza Master Fund Ltd.
		
	By:	 	 /s/ Brian Ladin

	 Name:
	 	 Brian Ladin

	 Title:
	 	 Managing Director

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 



			
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	DKR SoundShore Oasis Holding Fund Ltd.
		
	By:	 	 /s/ Barbara Burger

	 Name:
	 	 Barbara Burger

	 Title:
	 	 Alternate Director

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 



			
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	DKR SoundShore Strategic Holding Fund Ltd.
		
	By:	 	 /s/ Barbara Burger

	 Name:
	 	 Barbara Burger

	 Title:
	 	 Alternate Director

	
	 Address for Notice:

		
	 	 	 
	 	 	 



			
	 Facsimile No.
	 	 
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Bluegrass Growth Fund, L.P.
		
	By:	 	 /s/ Deborah Solomon

	 Name:
	 	 Deborah Solomon

	 Title:
	 	 Managing Member of Bluegrass Growth

	 Fund Partners, LLC, its general partner

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Bluegrass Growth Fund, Ltd.
		
	By:	 	 /s/ Brian Shatz

	 Name:
	 	 Brian Shatz

	 Title:
	 	 Director

	
	 Address for Notice:

		
	 	 	 



			
	 Facsimile No.
	 	 
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  
 <Signatures Continued on Following Page> 
  

 EXECUTION PAGE 









			
	PURCHASER:
	
	BayStar Capital II, L.P.
		
	By:	 	 /s/ Steve Derby

	 Name:
	 	 Steve Derby

	 Title:
	 	 General Partner of Bay East, LP, its

	 Managing Member

	
	 Address for Notice:

	
	 
	 



			
	 Facsimile No.
	 	 
	 Telephone No.
	 	 



			
	 Attention:
	 	 


  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Smithfield Fiduciary LLC
		
	By:	 	 /s/ Adam J. Chill

	 Name:
	 	 Adam J. Chill

	Title:	 	Authorized Signatory
	
	Address for Notice:
	
	 
	 



			
	Facsimile No.	 	 
	Telephone No.	 	 



			
	Attention:	 	 


  

 EXECUTION PAGE 









			
	PURCHASER:
	
	Omicron Master Trust
		
	By:	 	 /s/ Bruce Bernstein

	 Name:
	 	 Bruce Bernstein

	 Title:
	 	 Managing Partner

	
	 Address for Notice:

	
	 
	 



			
	Facsimile No.	 	 
	Telephone No.	 	 



			
	Attention:	 	 


  

 EXECUTION PAGE 









			
	PURCHASER:
	
	The Walters Group
		
	By:	 	 /s/ William T. Walters

	 Name:
	 	 William T. Walters

	Title:	 	General Partner
	
	Address for Notice:
	
	 
	 



			
	Facsimile No.	 	 
	Telephone No.	 	 



			
	Attention:	 	 


  

 EXECUTION PAGE 








 EXHIBIT A 
  

SCHEDULE OF PURCHASERS 
  

																			
	 Name and Address
 of
Purchaser

	  	State of
Residence

	  	Number
of Units

	  	 First
 Closing
Purchase
Price

	  	First
Closing
Shares

	  	First
Closing
Warrant
Shares

	  	Second
Closing
Purchase
Price

	  	Second
Closing
Shares

	  	Second
Closing
Warrant
Shares


	 Iroquois Capital, L.P.
	  	NY	  	88,601	  	$	924,994.44	  	177,202	  	44,300	  	$	924,994.44	  	177,202	  	44,301
	 Highline Capital Partners, LP
	  	NY	  	7,806	  	$	81,494.64	  	15,612	  	3,903	  	$	81,494.64	  	15,612	  	3,903
	 Highline Capital Partners, QP LP
	  	NY	  	20,320	  	$	212,140.80	  	40,640	  	10,160	  	$	212,140.80	  	40,640	  	10,160
	 Highline Capital International, Ltd.
	  	NY	  	43,713	  	$	456,363.72	  	87,426	  	21,856	  	$	456,363.72	  	87,426	  	21,857
	 Bonanza Master Fund Ltd.
	  	TX	  	47,892	  	$	499,992.48	  	95,784	  	23,946	  	$	499,992.48	  	95,784	  	23,946
	 DKR SoundShore Oasis Holding Fund Ltd.
	  	Bermuda	  	19,157	  	$	199,996.99	  	38,314	  	9,578	  	$	199,996.99	  	38,314	  	9,578
	 DKR SoundShore Strategic Holding Fund Ltd.
	  	Bermuda	  	4,789	  	$	49,999.25	  	9,578	  	2,395	  	$	49,999.25	  	9,578	  	2,395
	 Bluegrass Growth Fund, LP
	  	NY	  	17,959	  	$	187,491.96	  	35,918	  	8,979	  	$	187,491.96	  	35,918	  	`
8,980
	 Bluegrass Growth Fund, Ltd.
	  	NY	  	17,959	  	$	187,491.96	  	35,918	  	8,979	  	$	187,491.96	  	35,918	  	8,980
	 BayStar Capital II, L.P.
	  	CA	  	47,892	  	$	499,992.48	  	95,784	  	23,946	  	$	499,992.48	  	95,784	  	23,946
	 Smithfield Fiduciary LLC
	  	NY	  	71,839	  	$	749,999.16	  	143,678	  	35,919	  	$	749,999.16	  	143,678	  	35,920
	 Omicron Master Trust
	  	NY	  	35,919	  	$	374,994.36	  	71,838	  	17,959	  	$	374,994.36	  	71,838	  	17,960
	 The Walters Group
	  	NV	  	47,892	  	$	499,992.48	  	95,784	  	23,946	  	$	499,992.48	  	95,784	  	23,946
	 	  	 	  	 	  	 	 	  	943,476	  	 	  	 	 	  	943,476	  	 

  

 A-1 








 EXHIBIT B 
  

FORM OF WARRANT 
  
 NEITHER THIS WARRANT NOR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE
STATE SECURITIES LAW AND NEITHER MAY BE SOLD OR OTHERWISE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND SUCH APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (ii) THE COMPANY SHALL
HAVE RECEIVED A WRITTEN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER SUCH SECURITIES ACT AND SUCH APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER. ANY TRANSFER OF THIS
WARRANT OR THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF IS ALSO SUBJECT TO THE TERMS SET FORTH IN THIS WARRANT. 
  
 WARRANT TO PURCHASE 
 COMMON STOCK

 of 
 CORAUTUS
GENETICS INC. 
 Void after July     , 2009 
  
 This certifies that, for value received,
                                        ,
or registered assigns (“Holder”) is entitled, subject to the terms set forth below, to purchase from Corautus Genetics Inc., a Delaware corporation (the “Company”),
                    
(                    ) shares of the common stock, par value $0.001 per share (the “Common Stock”), of the Company, as
constituted on                     , 2004 (the “Warrant Issue Date”), upon surrender hereof, at the principal office of the
Company referred to below, with the notice of exercise form attached hereto duly executed, and simultaneous payment therefor in lawful money of the United States or otherwise as hereinafter provided, at the Exercise Price then in effect as set forth
in Section 2 below. The number, character and Exercise Price of such shares of Common Stock are subject to adjustment as provided below. The term “Warrant” as used herein shall mean this Warrant, which is one of a series of warrants
dated on or about the date hereof issued for shares of Common Stock of the Company (“Common Stock Warrants”) pursuant to that certain Common Stock and Warrant Purchase Agreement, dated July    , 2004,
between the Company and various purchasers (the “Purchase Agreement”). Capitalized terms used herein but not defined shall have the meaning ascribed to them in the Purchase Agreement. 
  
 1. Term of Warrant. Subject to the terms and conditions set forth
herein, this Warrant shall be exercisable, in whole or in part, during the term commencing on the Warrant Issue Date and ending at 5:00 p.m., eastern time, on July     , 2009 and shall be void thereafter. 
  

 B-1 








 2. Exercise Price. The exercise price at which this Warrant may be exercised shall be
$             per share of Common Stock, as adjusted from time to time pursuant to Section 10 hereof (such exercise price, as adjusted, referred to as the “Exercise
Price”). 
  
 3. Exercise of Warrant. 

 
 (a) The purchase rights represented by this Warrant are exercisable by the
Holder in whole or in part, but not for less than 1,000 shares at a time (or such lesser number of shares which may then constitute the maximum number purchasable; such number being subject to adjustment as provided in Section 10 below), at any
time, or from time to time, during the term hereof as described in Section 1 above, by the surrender of this Warrant and the Notice of Exercise annexed hereto duly completed and executed on behalf of the Holder, at the office of the Company (or such
other office or agency of the Company as it may designate by notice in writing to the Holder at the address of the Holder appearing on the books of the Company), upon payment in cash or by check acceptable to the Company of the purchase price of the
shares to be purchased. 
  
 (b) Notwithstanding any provisions
herein to the contrary, if the fair market value of one share of Common Stock is greater than the Exercise Price (calculated on a per share basis) therefor (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash,
the Holder may elect to receive shares of Common Stock equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company, in which event the Company
shall issue to the Holder that number of shares of Common Stock computed using the following formula: 
  

									
	 	  	 	  	 	  	PFD =	  	WPFD (FMV-EP)
	 	  	 	  	 	  	 	  	 FMV

	 Where:
	  	 	  	 	  	 	  	 
				
	 	  	PFD	  	=	  	the number of shares of Common Stock to be issued to the Holder
				
	 	  	WPFD	  	=	  	the number of shares of Common Stock purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the
date of such calculation)
				
	 	  	FMV	  	=	  	the fair market value of one share of Common Stock (at the date of such calculation) as determined below
				
	 	  	EP	  	=	  	Exercise Price (as adjusted to the date of such calculation) of this Warrant

  
 For purposes of the above calculation,
the fair market value of one share of Common Stock shall be determined by the Board, with the Holder’s representatives abstaining, in good faith; provided, however, that where there exists a public market for the Common Stock at
the time of such exercise, the fair market value per share shall be equal to the average of the closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary or the last reported sale price of the Common Stock or the
closing price quoted on the NASDAQ National 

  

 B-2 








 
Market System or on any exchange on which the Common Stock is listed, whichever is applicable, as published in The Wall Street Journal, averaged for the five
Trading Days prior to the date of determination of the fair market value. 
  
 (c) The person entitled to receive the shares of Common Stock issuable upon the foregoing exercise or deemed exercise shall be treated for all purposes as the holder of record of such shares as of the close of
business on such date. As promptly as practicable on or after such date and in any event within five days thereafter, the Company at its expense shall issue and deliver to the person or persons entitled to receive the same a certificate or
certificates for the number of shares issuable upon such exercise. In the event that this Warrant is exercised in part, the Company at its expense will execute and deliver a new Warrant of like tenor exercisable for the number of shares for which
this Warrant may then be exercised. 
  
 4. No Fractional Shares
or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. If any fraction of a Warrant Share would, except for the provisions of this Section, be issuable upon exercise of this
Warrant, the number of Warrant Shares to be issued will be rounded down to the nearest whole share and the Company will pay cash for the fraction. 
  
 5. Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company at
its expense shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount. 
  
 6. Rights of Stockholders. Subject to Section 10 of this Warrant, the Holder shall not be entitled to vote or receive dividends or be deemed
the holder of Common Stock or any other securities of the Company that may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a
stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of
stock, reclassification of stock, change of par value, or change of stock to no par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the
Warrant shall have been exercised as provided herein. 
  
 7.
Transfer of Warrant. 
  
 (a) Warrant Register. The
Company will maintain a register (the “Warrant Register”) containing the names and addresses of the Holder or Holders. Any Holder of this Warrant or any portion thereof may change his or her address as shown on the Warrant Register
by written notice to the Company requesting such change. Any notice or written communication required or permitted to be given to the Holder may be delivered or given by mail to such Holder as shown on the Warrant Register and at the address shown
on the Warrant Register. Until this Warrant is transferred on the Warrant Register of the Company, the Company may treat the 

  

 B-3 








 
Holder as shown on the Warrant Register as the absolute owner of this Warrant for all purposes, notwithstanding any notice to the contrary. 
  
 (b) Warrant Agent. The Company may, by written notice to the Holder,
appoint an agent for the purpose of maintaining the Warrant Register referred to in Section 7(a) above, issuing the Common Stock or other securities then issuable upon the exercise of this Warrant, exchanging this Warrant, replacing this Warrant, or
any or all of the foregoing. Thereafter, any such registration, issuance, exchange, or replacement, as the case may be, shall be made at the office of such agent. 
  
 (c) Transferability and Negotiability of Warrant. This Warrant may not be transferred or assigned in whole or in part
by the Company. This Warrant may not be transferred or assigned in whole or in part by the Holder without compliance with all applicable federal and state securities laws by the transferor and the transferee (including the delivery of investment
representation letters and legal opinions reasonably satisfactory to the Company, if such are requested by the Company). Subject to the provisions of this Warrant with respect to compliance with the Securities Act of 1933, as amended (the
“Securities Act”), and applicable state securities laws, title to this Warrant may be transferred by endorsement (by the Holder executing the Assignment Form annexed hereto) and delivery in the same manner as a negotiable instrument
transferable by endorsement and delivery. Any transfer of this Warrant is also subject to the provisions of Section 6.2 of the Purchase Agreement. 
  
 (d) Exchange of Warrant Upon a Transfer. On surrender of this Warrant for exchange, properly endorsed on the Assignment Form and subject to the
provisions of this Warrant with respect to compliance with the Securities Act and applicable state securities laws and with the limitations on assignments and transfers contained in this Section 7, the Company at its expense shall issue to or on the
order of the Holder new warrant or warrants of like tenor, in the name of the Holder or as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of shares issuable upon exercise hereof. 
  
 (e) Compliance with Securities Laws. 
  
 (i) The Holder of this Warrant, by acceptance hereof,
acknowledges that this Warrant and the shares of Common Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder will not
offer, sell or otherwise dispose of this Warrant or any shares of Common Stock to be issued upon exercise hereof or conversion thereof except under circumstances that will not result in a violation of the Securities Act or any applicable state
securities laws. Upon exercise of this Warrant, the Holder shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the shares of Common Stock so purchased are being acquired solely for the Holder’s
own account and not as a nominee for any other party, for investment, and not with a view toward distribution or resale. 
  

 B-4 








 (ii) All shares of Common Stock issued upon exercise hereof or conversion thereof shall
be stamped or imprinted with a legend in substantially the following form (in addition to any legend required by state securities laws): 
  
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 8. Reservation of Stock. The Company covenants that during the term this Warrant is exercisable, the Company will reserve from its authorized and
unissued Common Stock a sufficient number of shares to provide for the issuance of Common Stock upon the exercise of this Warrant and, from time to time, will take all steps necessary to amend its certificate of incorporation to provide sufficient
reserves of shares Common Stock issuable upon exercise of the Warrant. The Company further covenants that all shares that may be issued upon the exercise of rights represented by this Warrant and payment of the Exercise Price, all as set forth
herein, will be free from all taxes, liens and charges in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously or otherwise specified herein). The Company agrees that its issuance of this Warrant
shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock upon the exercise of this Warrant. 
  
 9. Amendments. 
  
 (a) Any term of this Warrant may be amended with the written consent of the
Company and the holders of warrants representing not less than fifty percent (50%) of the shares of Common Stock issuable upon exercise of any and all outstanding Common Stock Warrants, even without the consent of the Holder. Any amendment effected
in accordance with this Section 9 shall be binding upon each holder of any of the Common Stock Warrants, each future holder of all such Common Stock Warrants, and the Company; provided, however, that no special consideration or
inducement may be given to any such holder in connection with such consent that is not given ratably to all such holders, and that such amendment must apply to all such holders equally and ratably in accordance with the number of shares of Common
Stock issuable upon exercise of their Common Stock Warrants. The Company shall promptly give notice to all holders of Common Stock Warrants of any amendment effected in accordance with this Section 9. 
  
 (b) No waivers of, or exceptions to, any term, condition or provision of this
Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 
  
 10. Adjustments. The Exercise Price and the number of shares purchasable hereunder are subject to adjustment from time to time as follows:

  
 (a) Merger, Sale of Assets, etc. If at any time while
this Warrant, or any portion thereof, is outstanding and unexpired there shall be (i) a reorganization (other than a combination, reclassification, exchange or subdivision of shares otherwise provided for herein), (ii) a merger or consolidation of
the Company with or into another corporation in which the Company is not the surviving entity, or a reverse triangular merger in which the Company is the surviving entity but the shares of the Company’s capital stock outstanding immediately
prior to 

  

 B-5 








 
the merger are converted by virtue of the merger into other property, whether in the form of securities, cash, or otherwise, or (iii) a sale or transfer of
the Company’s properties and assets as, or substantially as, an entirety to any other person, then, as a part of such reorganization, merger, consolidation, sale or transfer, lawful provision shall be made so that the Holder of this Warrant
shall thereafter be entitled to receive upon exercise of this Warrant, during the period specified herein and upon payment of the Exercise Price then in effect, the number of shares of stock or other securities or property of the successor
corporation resulting from such reorganization, merger, consolidation, sale or transfer that a holder of the shares deliverable upon exercise of this Warrant would have been entitled to receive in such reorganization, consolidation, merger, sale or
transfer if this Warrant had been exercised immediately before such reorganization, merger, consolidation, sale or transfer, all subject to further adjustment as provided in this Section 10. The foregoing provisions of this Section 10(a) shall
similarly apply to successive reorganizations, consolidations, mergers, sales and transfers and to the stock or securities of any other corporation that are at the time receivable upon the exercise of this Warrant. If the per-share consideration
payable to the Holder hereof for shares in connection with any such transaction is in a form other than cash or marketable securities, then the value of such consideration shall be determined in good faith by the Company’s Board of Directors.
In all events, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after the
transaction, to the end that the provisions of this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any shares or other property deliverable after that event upon exercise of this Warrant. 
  
 (b) Reclassification, etc. If the Company, at any time while this
Warrant, or any portion hereof, remains outstanding and unexpired by reclassification of securities or otherwise, shall change any of the securities as to which purchase rights under this Warrant exist into the same or a different number of
securities of any other class or classes, this Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities that were subject to
the purchase rights under this Warrant immediately prior to such reclassification or other change and the Exercise Price therefor shall be appropriately adjusted, all subject to further adjustment as provided in this Section 10. 
  
 (c) Split, Subdivision or Combination of Shares. If the Company at any
time while this Warrant, or any portion hereof, remains outstanding and unexpired shall split, subdivide or combine the securities as to which purchase rights under this Warrant exist, into a different number of securities of the same class, the
Exercise Price for such securities shall be proportionately decreased in the case of a split or subdivision or proportionately increased in the case of a combination. Upon each adjustment in the Exercise Price pursuant to this subsection, the number
of shares of such securities purchasable hereunder shall be adjusted, to the nearest whole share, to the product obtained by multiplying the number of shares purchasable immediately prior to such adjustment in the Exercise Price by a fraction, the
numerator of which shall be the Exercise Price immediately prior to such adjustment and the denominator of which shall be the Exercise Price immediately thereafter. 
  
 (d) Adjustments for Dividends in Stock or Other Securities or Property. If while this Warrant, or any portion hereof,
remains outstanding and unexpired the holders of the securities 

  

 B-6 








 
as to which purchase rights under this Warrant exist at the time shall have received, or, on or after the record date fixed for the determination of eligible
stockholders, shall have become entitled to receive, without payment therefor, other or additional stock or other securities or property (other than cash) of the Company by way of dividend (except for distributions specifically provided for in the
foregoing subsection (b) and (c) of this Section 10), then and in each case, this Warrant shall represent the right to acquire, in addition to the number of shares of the security receivable upon exercise of this Warrant, and without payment of any
additional consideration therefor, the amount of such other or additional stock or other securities or property (other than cash) of the Company that such holder would hold on the date of such exercise had it been the holder of record of the
security receivable upon exercise of this Warrant on the date hereof and had thereafter, during the period from the date hereof to and including the date of such exercise, retained such shares and/or all other additional stock available by it as
aforesaid during such period, giving effect to all adjustments called for during such period by the provisions of this Section 10. 
  
 (e) Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 10, the Company at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this Warrant a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such
adjustment or readjustment is based. The Company shall, upon the written request, at any time, of any such Holder, furnish or cause to be furnished to such Holder a like certificate setting forth: (i) such adjustments and readjustments; (ii) the
Exercise Price at the time in effect; and (iii) the number of shares and the amount, if any, of other property that at the time would be received upon the exercise of the Warrant. 
  
 (f) No Impairment. The Company will not, by any voluntary action, avoid or seek to avoid the observance or
performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Section 10 and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Holder of this Warrant against impairment. 
  
 11. Governing Law. This Warrant shall be governed by, and construed in accordance with, the laws of the State of New York. 
  
 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its duly authorized officer as of the
       day of                     , 2004. 
  

			
	CORAUTUS GENETICS INC.
		
	By:	 	 
	 Richard E. Otto, Chief Executive Officer



  

 B-7 








 NOTICE OF EXERCISE 
  
 TO: CORAUTUS GENETICS INC. 
  
 (1) The undersigned hereby elects to purchase
                     shares of Common Stock of CORAUTUS GENETICS INC., pursuant to the provisions of Section 3(a) of the attached Warrant, and
tenders herewith payment of the purchase price for such shares in full. 
  
 (2) In exercising this Warrant, the undersigned hereby confirms and acknowledges that the shares of Common Stock are being acquired solely for the account of the undersigned and not as a nominee for any other party, and for investment, and
that the undersigned will not offer, sell or otherwise dispose of any such shares of Common Stock except under circumstances that will not result in a violation of the Securities Act of 1933, as amended, or any applicable state securities laws.

  
 (3) Please issue a certificate or certificates representing
said shares of Common Stock in the name of the undersigned or in such other name as is specified below: 
  

	
	
	 
	 (Name)

	
	 
	 (Name)



  
 (4) Please issue
a new Warrant for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as is specified below: 
  

					
			
	  	 	 	 	  
	 	 	 	 	 (Name)

			
	  	 	 	 	  
	 (Date)
	 	 	 	 (Signature)


  

 B-8 








 ASSIGNMENT FORM 
  
 FOR VALUE RECEIVED, the undersigned registered owner of this Warrant hereby sells, assigns and transfer unto the Assignee
named below all of the rights of the undersigned under the within Warrant, with respect to the number of shares of or Common Stock set forth below: 
  

					
	 Name of Assignee

	  	 Address

	  	 No. of Shares


	 	  	 	  	 
	 	  	 	  	 

  
 and does hereby irrevocably constitute
and appoint                      attorney to make such transfer on the books of CORAUTUS GENETICS INC. maintained for the purpose, with full
power of substitution in the premises. 
  
 The undersigned also
represents that, by assignment hereof, the Assignee acknowledges that this Warrant and the shares of stock to be issued upon exercise hereof or conversion thereof are being acquired for investment and that the Assignee will not offer, sell or
otherwise dispose of this Warrant or any shares of stock to be issued upon exercise hereof or conversion thereof except under circumstances which will not result in a violation of the Securities Act of 1933, as amended, or any state securities laws.
Further, the Assignee acknowledges that upon exercise of this Warrant, the Assignee shall, if requested by the Company, confirm in writing, in a form satisfactory to the Company, that the shares of stock so purchased are being acquired for
investment and not with a view toward distribution or resale. 
  

									
					
	 Dated:
	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 Signature of Holder


  

 B-9 








 EXHIBIT C 
  

FORM OF INSTRUCTION TO TRANSFER AGENT 
  

 C-1 








                     , 200     
  
 Mr. William Garza 
 US Stock Transfer
Corporation 
 1745 Gardena Avenue 
 Glendale, CA 91204

  
 Dear Mr. Garza, 
  
 Please accept this letter as authorization to issue one certificate to
                         for
                     shares of common stock, par value $0.001 per share, of Corautus Genetics Inc. (“Corautus”), and so record such
issuance on the stock register. [Please only issue the certificate upon further instructions to you by Corautus confirming that the escrow funds for the second tranche have been released to Corautus].1 The certificate shall be dated
                    , 200    . In addition, please affix the following legend on the certificate: 
  
 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTION. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE DISTRIBUTION
THEREOF. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO AN
EXEMPTION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. 
  
 Finally, please deliver the new certificate to the stockholder’s address of record, which is as follows: 
  
 _________________________ 
  
 _________________________ 
  
 _________________________ 
  
 Thank you for your attention in this matter. Should you have any questions, please do not hesitate to contact me. 
  

	
	Sincerely,
	
	 
	 Jack Callicutt

	 Vice President- Finance and Administration



  

	cc:	Richard E. Otto, Chief Executive Officer 

  


	1	Only applicable to the Second Closing. 

  

 C-2 








 EXHIBIT D 
  

COMPANY DISCLOSURE SCHEDULE 
  

			
		
	4.9	  	On May 7, 2004, eleven current or former directors and officers of the Company purchased an aggregate of 91,909 shares of unregistered common stock from the company at $5.50 per share for
aggregate proceeds to the Company of $505,500.
		
	4.11	  	Certain material, non-public information may have been provided to Vertical Ventures, LLC pursuant to a Non-Disclosure Agreement by and between the Company and Vertical Ventures, LLC dated
March 19, 2004.

  

 D-1 








 EXHIBIT E 
  

PLAN OF DISTRIBUTION 
  
 The selling stockholders may, from time to time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on
which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling stockholders may use any one or more of the following methods when selling shares: 
  

	 	•	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;


  

	 	•	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	privately negotiated transactions; 

  

	 	•	short sales; 

  

	 	•	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	a combination of any such methods of sale; and 

  

	 	•	any other method permitted pursuant to applicable law. 

  
 The selling stockholders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus. 
  
 The selling stockholders may also engage in short sales against the box, puts
and calls and other transactions in our securities or derivatives of our securities and may sell or deliver shares in connection with these trades. 
  
 Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is
customary in the types of transactions involved. Any profits on the resale of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. Discounts, concessions,
commissions and similar selling expenses, if any, attributable to the sale of shares will be borne by a selling stockholder. The selling stockholders may agree to indemnify any 

  

 E-1 








 
agent, dealer or broker-dealer that participates in transactions involving sales of the shares if liabilities are imposed on that person under the Securities
Act. 
  
 The selling stockholders may from time to time pledge or
grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to
time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. 
  
 The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus and
may sell the shares of common stock from time to time under this prospectus after we have filed an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of selling
stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. 
  
 The selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be
“underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act. 
  
 We are required to pay all fees and expenses incident to the registration of the shares of common stock. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities,
including liabilities under the Securities Act. 
  
 The selling
stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their shares of common stock, nor is there an underwriter or coordinating
broker acting in connection with a proposed sale of shares of common stock by any selling stockholder. If we are notified by any selling stockholder that any material arrangement has been entered into with a broker-dealer for the sale of shares of
common stock, if required, we will file a supplement to this prospectus. If the selling stockholders use this prospectus for any sale of the shares of common stock, they will be subject to the prospectus delivery requirements of the Securities Act.

  
 The anti-manipulation rules of Regulation M under the
Securities Exchange Act of 1934 may apply to sales of our common stock and activities of the selling stockholders. 
  

 C-2